BBOT Stock Forecast & Price Target

BridgeBio Oncology is attractive because its three-program RAS platform is strategically differentiated, spanning KRAS G12C, pan-KRAS, and a RAS–PI3Kα breaker, which creates multiple shots on goal across KRAS-mutant CRC, PDAC, and NSCLC. The lead asset BBO-8520 has shown a 75% ORR with pembrolizumab in 2L+ KRAS G12C inhibitor-experienced NSCLC and a 63% ORR as monotherapy, with no grade 3 liver enzyme elevations, supporting both efficacy and tolerability. The broader pipeline adds meaningful upside through expected 4Q26 and mid-2027 data readouts, while modeled worldwide peak sales of about $7.5bn highlight substantial long-term commercial potential as the company advances internal combinations.

BridgeBio Oncology is facing a weak fundamental setup because its pipeline streamlining has narrowed the growth narrative, deprioritized breast cancer programs, and pushed investors to strip legacy indications from models, which helped drive the shares down 24% versus XBI -1.6% today. Although BBO-8520 showed a 75% ORR in 17 KRAS G12C-experienced NSCLC patients at the 500mg QD dose, the move into the 2L+ setting reduces the size of the opportunity, while BBO-11818 and BBO-10203 remain early with limited monotherapy and combo data expected only in mid-2027. With all three assets still in Phase 1, BBOT faces meaningful clinical, regulatory, and financing risk, including large Phase 3 capital needs and likely future equity issuance that could dilute shareholders in a highly competitive RAS and PI3K landscape.